clinical trial · NCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Janssen Research & Development, LLC·phase1·recruiting·n = 340
Lymphoma, Non-HodgkinJNJ-95566692JNJ-87801493loncastuximab tesirineLenalidomideRituximabGemcitabineOxaliplatinCyclophosphamide
brief summary
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.
started
Jan 20, 2026
primary completion
Aug 31, 2028
completion
Oct 31, 2029
last updated
Sep 10, 2026
official title
A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol